Accessibility Menu
Beximco Pharmaceuticals Plc. logo

Beximco Pharmaceuticals Plc.(LSE) BXP

Market Cap£249.82MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2005)+352%
5 Year-34%
1 Year+14%
1 Month+7%
£0.56
+0.18%
+0.00Today
Beximco Pharmaceuticals Plc. last closing stock price
MetricPriceDate
Last closeGBX 56.002026-08-20
Beximco Pharmaceuticals Plc. stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+1.82%GBX 55.002026-08-13
1 month+6.67%GBX 52.502026-07-21
3 month+31.76%GBX 42.502026-01-26
Year to date+31.76%GBX 42.502025-12-31
1 year+14.29%GBX 49.002025-08-20
3 year+40%GBX 40.002023-08-21
5 year-34.12%GBX 85.002021-08-20
Since inception+352.49%GBX 0.122005-10-21

Beximco Pharmaceuticals Plc. Financials at a Glance

Market Cap

£249.82MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

BDT 53.26B

Net Income (TTM)

BDT 8.69B

EPS (TTM)

£0.12

P/E Ratio

4.73

Dividend

£0.03

Beta (Volatility)

0.04 (Low)

Price

£0.56

Volume

16,177

Open

£0.56

Previous Close

£0.56

Daily Range

£0.56 - £0.57

52-Week Range

£0.37 - £0.57

Estimated Earnings Date

Sep 2, 2026

BXP News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Beximco Pharmaceuticals Plc.

Established in 1976 and headquartered in Dhaka, Bangladesh, Beximco Pharmaceuticals Limited is a prominent company engaged in the production and distribution of generic pharmaceutical formulations and active pharmaceutical ingredients (APIs). The firm’s extensive product line addresses a wide range of therapeutic areas, including treatments for various health conditions.

Products and Services
  • Generic pharmaceutical formulations across multiple therapeutic areas
  • Active pharmaceutical ingredients (APIs) for various medications
  • Contract manufacturing services for other pharmaceutical companies
Growth Outlook
  • Strong demand for generic drugs supports revenue growth potential
  • Expansion into international markets enhances global footprint
  • Investment in R&D to innovate and diversify product offerings
Financial Highlights
  • Recent quarterly revenue of 13.20 billion BDT, reflecting robust sales
  • Trailing twelve months (TTM) net profit margin of 16.76%, indicating profitability
  • Current ratio of 4.13, showcasing strong liquidity position
Beximco Pharmaceuticals Limited has established itself as a key player in the pharmaceutical industry, focusing on generic medications and APIs. The company's diverse product offerings cater to a wide range of therapeutic needs, from chronic diseases to acute conditions. With a strong emphasis on quality and compliance, Beximco is well-positioned to capitalize on the growing global demand for affordable healthcare solutions. The growth outlook for Beximco Pharmaceuticals is promising, driven by increasing demand for generic drugs and strategic expansion into international markets. The company's commitment to research and development is expected to foster innovation and enhance its product portfolio, further solidifying its market position. Financially, Beximco has demonstrated resilience, with a recent quarterly revenue of 13.20 billion BDT, showcasing its ability to generate substantial sales. The TTM net profit margin of 16.76% reflects effective cost management and operational efficiency. Additionally, a current ratio of 4.13 indicates a strong liquidity position, providing the company with the flexibility to navigate market challenges and invest in future growth opportunities.
AI Generated • Jul 31, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

1,223

CEO

Iqbal Ahmed

Website

www.beximcopharma.com

Headquarters

Dhaka, DA 1205, BD

BXP Financials

Key Financial Metrics (TTM)

Gross Margin

46.33%

Operating Margin

21.98%

Net Income Margin

16.76%

Return on Equity

11.99%

Return on Capital

16.07%

Return on Assets

8.86%

Earnings Yield

21.14%

Dividend Yield

5.11%

Payout Ratio

2.91%

Stock Overview

Market Cap

£249.82MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

446.11M

Volume

16.18K

Avg. Volume

71.16K

Financials (TTM)

Gross Profit

BDT 24.55B

Operating Income

BDT 11.53B

EBITDA

BDT 12.59B

Operating Cash Flow

BDT 8.43B

Capital Expenditure

-BDT 3.97B

Free Cash Flow

BDT 4.45B

Cash & ST Invst.

BDT 5.15B

Total Debt

BDT 3.11B

Beximco Pharmaceuticals Plc. Performance Analysis

Beximco Pharmaceuticals Plc. annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-06-30BDT 302,002,896N/A
20232023-06-30BDT 316,780,9634.9%
20242024-06-30BDT 318,188,2770.4%
20252025-06-30BDT 315,190,850-0.9%
Beximco Pharmaceuticals Plc. sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-12-315.0%
Q12025-09-30N/A
Q22025-12-314.7%
Q32026-03-31-7.1%
Beximco Pharmaceuticals Plc. annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-06-30BDT 0.10N/A
20232023-06-30BDT 0.08-16.6%
20242024-06-30BDT 0.0912.4%
20252025-06-30BDT 0.106.5%
Beximco Pharmaceuticals Plc. sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-12-318.8%
Q12025-09-30N/A
Q22025-12-312.9%
Q32026-03-31-9.9%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q3 2025YOY CHG

Revenue

BDT 13.20B

+12.7%

Gross Profit

BDT 5.83B

+7.8%

Gross Margin

44.17%

N/A

Market Cap

£249.82MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

£41.64K

N/A

Employees

6,000

N/A

Net Income

BDT 2.15B

+27.9%

EBITDA

BDT 3.28B

+11.1%

Quarterly Fundamentals

Name
Q3 2025YOY CHG

Total Cash

BDT 5.15B

+293.3%

Total Debt

BDT 3.11B

+48.7%

Accounts Receivable

BDT 3.78B

-44.2%

Inventory

BDT 15.31B

+8.2%

Long Term Debt

BDT 1.28B

+11248.6%

Short Term Debt

BDT 1.84B

-12.3%

Return on Assets

8.86%

N/A

Return on Invested Capital

12.72%

N/A

Free Cash Flow

BDT 2.22B

+60.3%

Operating Cash Flow

BDT 2.41B

+42.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
OPT.LOptima Health plc
£2.38+0.00%
ANCR.LAnimalcare Group plc
£3.35+0.45%
TSTL.LTristel PLC
£4.25+0.59%
DXRX.LDiaceutics PLC
£1.37-4.20%

Trending Stocks

Symbol / CompanyPricePrice Chg
BITOProShares Trust - ProShares Bitcoin ETF
$9.81+0.06%
SPCXSpace Exploration Technologies
$134.00-0.04%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$8.88-0.03%
IBITiShares Bitcoin Trust
$41.20+0.06%

Questions About BXP

What is the current price of Beximco Pharmaceuticals Plc.?

Beximco Pharmaceuticals Plc. is trading at £0.56 per share.

What is the 52-week range for Beximco Pharmaceuticals Plc.?

Over the past 52 weeks, Beximco Pharmaceuticals Plc. has traded between £0.37 and £0.57.

How much debt does Beximco Pharmaceuticals Plc. have?

As of the most recent reporting period, Beximco Pharmaceuticals Plc. reported total debt of BDT 19.49M.

How much cash does Beximco Pharmaceuticals Plc. have on hand?

Beximco Pharmaceuticals Plc. reported BDT 26.38M in cash and cash equivalents in its most recent financial results.

What is Beximco Pharmaceuticals Plc.’s dividend yield?

Beximco Pharmaceuticals Plc. currently has a dividend yield of 5.11%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services